UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

3D filling simulation of micro- and nanostructures in comparison to iso- and variothermal injection moulding trials

Journal of micromechanics and microengineering, 2016-06, Vol.26 (6), p.65018

2016

Volltextzugriff (PDF)

Treatments for EGFR Mutation-Positive (M+) NSCLC Patients – A Network Meta-Analysis (NMA) by Mutation Type

Value in health, 2014-11, Vol.17 (7), p.A615-A615

2014

Volltextzugriff (PDF)

What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study

Lung cancer (Amsterdam, Netherlands), 2013-10, Vol.82 (1), p.128-135

2013

Volltextzugriff (PDF)

Treatments for EGFR Mutation Positive NSCLC – A Network Meta-Analysis

Value in health, 2013-11, Vol.16 (7), p.A396-A396

2013

Volltextzugriff (PDF)

Investigation into reduction of die-cavity deflection in micro-hydroforming processes using FEA

International journal of advanced manufacturing technology, 2010-04, Vol.47 (9-12), p.853-858

2010

Volltextzugriff (PDF)

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S11-S11

2013

Volltextzugriff (PDF)

PCN110 Health-Related Quality of Life in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Value in health, 2012-06, Vol.15 (4), p.A227-A227

2012

Volltextzugriff (PDF)

Process Parameter Optimization for Wobbling Laser Spot Welding of Ti6Al4V Alloy

Physics procedia, 2016, Vol.83, p.483-493

2016

Volltextzugriff (PDF)

Evaluation of Association of Progression-Free Survival (Pfs) with Health-Related Quality of Life (Hrqol) in Lung Cancer Patients (Pts)

Annals of oncology, 2014-09, Vol.25, p.iv446

2014

Volltextzugriff (PDF)

1268PEVALUATION OF ASSOCIATION OF PROGRESSION-FREE SURVIVAL (PFS) WITH HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN LUNG CANCER PATIENTS (PTS)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv446-iv446

2014

Volltextzugriff (PDF)

PCN8 - Treatments for EGFR Mutation-Positive (M+) NSCLC Patients – A Network Meta-Analysis (NMA) by Mutation Type

Value in health, 2014-11, Vol.17 (7), p.A615-A615

2014

Volltextzugriff (PDF)

The Impact Of First-Line Tyrosine Kinase Inhibitors (Tkis) On Overall Survival In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) And Activating Epidermal Growth Factor Receptor (Egfr) Mutations: Meta-Analysis Of Major Randomized Trials By Mutation Type

Value in health, 2015-11, Vol.18 (7), p.A436-A436

2015

Volltextzugriff (PDF)

PCN40 - The Impact Of First-Line Tyrosine Kinase Inhibitors (Tkis) On Overall Survival In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) And Activating Epidermal Growth Factor Receptor (Egfr) Mutations: Meta-Analysis Of Major Randomized Trials By Mutation Type

Value in health, 2015-11, Vol.18 (7), p.A436-A436

2015

Volltextzugriff (PDF)

PCN24 - Treatments for EGFR Mutation Positive NSCLC – A Network Meta-Analysis

Value in health, 2013-11, Vol.16 (7), p.A396-A396

2013

Volltextzugriff (PDF)

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv444-iv444

2014

Volltextzugriff (PDF)

Patient-Reported Outcomes (Pros) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) Receiving Afatinib (A) Monotherapy Followed By a + Paclitaxel (A + P) Vs Investigator'S Choice of Single-Agent Chemotherapy (Ic): Lux-Lung 5 (Ll5)

Annals of oncology, 2014-09, Vol.25, p.iv444

2014

Volltextzugriff (PDF)

1251PUPDATED ANALYSIS OF RESPONSE AND PATIENT-REPORTED OUTCOMES (PRO) IN TWO LARGE OPEN-LABEL, PHASE III STUDIES (LUX-LUNG 3 [LL3] AND LUX-LUNG 6 [LL6]) OF AFATINIB (A) VERSUS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH ADVANCED NSCLC HARBORING EGFR MUTATIONS (MUT)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv439-iv439

2014

Volltextzugriff (PDF)

Updated Analysis of Response and Patient-Reported Outcomes (Pro) in Two Large Open-Label, Phase III Studies (Lux-Lung 3 [Ll3] and Lux-Lung 6 [Ll6]) of Afatinib (A) Versus Chemotherapy (Ct) in Patients (Pts) with Advanced Nsclc Harboring Egfr Mutations (Mut)

Annals of oncology, 2014-09, Vol.25, p.iv439

2014

Volltextzugriff (PDF)

Lux-Lung 3: Symptom and Health-Related Quality of Life Results from a Randomized Phase III Study in 1st-Line Advanced NSCLC Patients Harbouring EGFR Mutations

Annals of oncology, 2012-09, Vol.23, p.ix402

2012

Volltextzugriff (PDF)

PCV122 ANGIOGRAPHY FOR DIAGNOSING PAOD: COST COMPARISON OF THE DIAGNOSTIC PROCEDURES MRA AND DSA

Value in health, 2009, Vol.12 (7), p.A335-A336

2009

Volltextzugriff (PDF)

Cost-Effectiveness of Strong Opioids Focussing on the Long-Term Effects of Opioid-Related Fractures: A Model Approach

The European journal of health economics, 2009-07, Vol.10 (3), p.309-321

2009

Volltextzugriff (PDF)

PCV35 GADOFOSVESET IN THE MANAGEMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN CANADA-A MODEL APPROACH FOCUSING ON DIAGNOSTIC CONFIDENCE

Value in health, 2008-05, Vol.11 (3), p.A196-A196

2008

Volltextzugriff (PDF)

PSY16 COST-EFFECTIVENESS OFTRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY— A MODEL APPROACH

Value in health, 2008, Vol.11 (3), p.A157-A157

2008

Volltextzugriff (PDF)

PRS9 ESTIMATED COST SAVINGS ASSOCIATED WITH THE USE OF A NEW TASTE-MASKED ORAL CLARITHROMYCIN PREPARATION FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN CHILDREN IN GERMANY

Value in health, 2007, Vol.10 (3), p.A179-A180

2007

Volltextzugriff (PDF)

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3342-3350

2013

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(38)
Deutsch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

3D filling simulation of micro- and nanostructures in comparison to iso- and variothermal injection moulding trials

Treatments for EGFR Mutation-Positive (M+) NSCLC Patients – A Network Meta-Analysis (NMA) by Mutation Type

What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study

Treatments for EGFR Mutation Positive NSCLC – A Network Meta-Analysis

Investigation into reduction of die-cavity deflection in micro-hydroforming processes using FEA

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

PCN110 Health-Related Quality of Life in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Process Parameter Optimization for Wobbling Laser Spot Welding of Ti6Al4V Alloy

Evaluation of Association of Progression-Free Survival (Pfs) with Health-Related Quality of Life (Hrqol) in Lung Cancer Patients (Pts)

1268PEVALUATION OF ASSOCIATION OF PROGRESSION-FREE SURVIVAL (PFS) WITH HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN LUNG CANCER PATIENTS (PTS)

PCN8 - Treatments for EGFR Mutation-Positive (M+) NSCLC Patients – A Network Meta-Analysis (NMA) by Mutation Type

The Impact Of First-Line Tyrosine Kinase Inhibitors (Tkis) On Overall Survival In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) And Activating Epidermal Growth Factor Receptor (Egfr) Mutations: Meta-Analysis Of Major Randomized Trials By Mutation Type

PCN40 - The Impact Of First-Line Tyrosine Kinase Inhibitors (Tkis) On Overall Survival In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) And Activating Epidermal Growth Factor Receptor (Egfr) Mutations: Meta-Analysis Of Major Randomized Trials By Mutation Type

PCN24 - Treatments for EGFR Mutation Positive NSCLC – A Network Meta-Analysis

1265PPATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING AFATINIB (A) MONOTHERAPY FOLLOWED BY A + PACLITAXEL (A + P) VS INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC): LUX-LUNG 5 (LL5)

Patient-Reported Outcomes (Pros) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) Receiving Afatinib (A) Monotherapy Followed By a + Paclitaxel (A + P) Vs Investigator'S Choice of Single-Agent Chemotherapy (Ic): Lux-Lung 5 (Ll5)

1251PUPDATED ANALYSIS OF RESPONSE AND PATIENT-REPORTED OUTCOMES (PRO) IN TWO LARGE OPEN-LABEL, PHASE III STUDIES (LUX-LUNG 3 [LL3] AND LUX-LUNG 6 [LL6]) OF AFATINIB (A) VERSUS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH ADVANCED NSCLC HARBORING EGFR MUTATIONS (MUT)

Updated Analysis of Response and Patient-Reported Outcomes (Pro) in Two Large Open-Label, Phase III Studies (Lux-Lung 3 [Ll3] and Lux-Lung 6 [Ll6]) of Afatinib (A) Versus Chemotherapy (Ct) in Patients (Pts) with Advanced Nsclc Harboring Egfr Mutations (Mut)

Lux-Lung 3: Symptom and Health-Related Quality of Life Results from a Randomized Phase III Study in 1st-Line Advanced NSCLC Patients Harbouring EGFR Mutations

PCV122 ANGIOGRAPHY FOR DIAGNOSING PAOD: COST COMPARISON OF THE DIAGNOSTIC PROCEDURES MRA AND DSA

Cost-Effectiveness of Strong Opioids Focussing on the Long-Term Effects of Opioid-Related Fractures: A Model Approach

PCV35 GADOFOSVESET IN THE MANAGEMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN CANADA-A MODEL APPROACH FOCUSING ON DIAGNOSTIC CONFIDENCE

PSY16 COST-EFFECTIVENESS OFTRANSDERMAL OPIOIDS REGARDING OPIOID-RELATED FRACTURES IN GERMANY— A MODEL APPROACH

PRS9 ESTIMATED COST SAVINGS ASSOCIATED WITH THE USE OF A NEW TASTE-MASKED ORAL CLARITHROMYCIN PREPARATION FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS IN CHILDREN IN GERMANY

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Suchergebnisse filtern